Peroxisome proliferator-activated receptor-γ antagonists GW9662 and T0070907 reduce the protective effects of lipopolysaccharide preconditioning against organ failure caused by endotoxemia

Critical Care Medicine

Volumn 34, Issue 4, 2006, Pages 1131-1138

  Collin, Marika ^a   Murch, Oliver ^a   Thiemermann, Christoph ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Endotoxemia; GW9662; Parecoxib; Peroxisome proliferator activated receptor ; Preconditioning; T0070907

Indexed keywords

2 CHLORO 5 NITRO N (4 PYRIDYL)BENZAMIDE; 2 CHLORO 5 NITROBENZANILIDE; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATININE; CYCLOOXYGENASE 2 INHIBITOR; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; INTERLEUKIN 1BETA; PARECOXIB; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG EFFECT; ENDOTOXEMIA; ISCHEMIA; KIDNEY DYSFUNCTION; LIVER CELL DAMAGE; LOW DRUG DOSE; MALE; MULTIPLE ORGAN FAILURE; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTECTION; PROTEIN BLOOD LEVEL; RANDOMIZATION; RAT; RAT STRAIN;

ANILIDES; ANIMALS; BENZAMIDES; ENDOTOXEMIA; LIPOPOLYSACCHARIDES; MALE; MULTIPLE ORGAN FAILURE; PYRIDINES; RATS; RATS, WISTAR;

EID: 33645808481     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000206472.63040.6D     Document Type: Article

References (54)

1. Kliewer SA, Umesono K, Noonan DJ, et al: Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature 1992; 358:771-774
2. Berger J, Moller DE: The mechanisms of action of PPARs. Annu Rev Med 2002; 53:409-435
3. Issemann I, Green S: Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990; 347:645-650
4. Willson TM, Brown PJ, Sternbach DD, et al: The PPARs: From orphan receptors to drug discovery. J Med Chem 2000; 43:527-550
5. Wayman NS, Hattori Y, McDonald MC, et al: Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size. FASEB J 2002; 16:1027-1040
6. Khandoudi N, Delerive P, Berrebi-Bertrand I, et al: Rosiglitazone, a peroxisome proliferator-activated receptor-gamma, inhibits the Jun NH(2)-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/reperfusion injury. Diabetes 2002; 51:1507-1514
7. Yue Tl TL, Chen J, Bao W, et al: In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Circulation 2001; 104:2588-2594
8. Meng X, Brown JM, Ao L, et al: Myocardial gene reprogramming associated with a cardiac cross-resistant state induced by LPS preconditioning. Am J Physiol 1998; 275:C475-C483
9. Meng X, Brown JM, Ao L, et al: Reduction of infarct size in the rat heart by LPS preconditioning is associated with expression of angiogenic growth factors and increased capillary density. Shock 1999; 12:25-31
10. Chatterjee PK, Patel NS, Cuzzocrea S, et al: The cyclopentenone prostaglandin 15-deoxy-Delta(12,14)-prostaglandin J2 ameliorates ischemic acute renal failure. Cardiovasc Res 2004; 61:630-643
11. Sivarajah A, Chatterjee PK, Patel NS, et al: Agonists of peroxisome-proliferator activated receptor-gamma reduce renal ischemia/ reperfusion injury. Am J Nephrol 2003; 23:267-276
12. Okada M, Yan SF, Pinsky DJ: Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) activation suppresses ischemic induction of Egr-1 and its inflammatory gene targets. FASEB J 2002; 16;1861-1868
13. Cuzzocrea S, Pisano B, Dugo L, et al: Rosiglitazone and 15-deoxy-Deltal2,14-prostaglandin J2, ligands of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), reduce ischaemia/reperfusion injury of the gut. Br J Pharmacol 2003; 140:366-376
14. Nakajima A, Wada K, Miki H, et al: Endogenous PPAR gamma mediates anti-inflammatory activity in murine ischemia-reperfusion injury. Gastroenterology 2001; 120:460-469
15. Ichikawa H, Naito Y, Takagi T, et al: A specific peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ligand, pioglitazone, ameliorates gastric mucosal damage induced by ischemia and reperfusion in rats. Redox Rep 2002; 7:343-346
16. Naito Y, Takagi T, Uchiyama K, et al: Suppression of intestinal ischemia-reperfusion injury by a specific peroxisome proliferator-activated receptor-gamma ligand, pioglitazone, in rats. Redox Rep 2002; 7:294-299
17. Zingarelli B, Sheehan M, Hake PW, et al: Peroxisome proliferator activator receptor-gamma ligands, 15-deoxy-Delta(12,14)-prostaglandin J2 and ciglitazone, reduce systemic inflammation in polymicrobial sepsis by modulation of signal transduction pathways. J Immunol 2003; 171:6827-6837
18. Collin M, Thiemermann C: The PPAR-gamma ligand 15-deoxy(delta12,14) prostaglandin J2 reduces the liver injury in endotoxic shock. Eur J Pharmacol 2003; 476:257-258
19. Collin M, Patel NS, Dugo L, et al: Role of peroxisome proliferator-activated receptor-gamma in the protection afforded by 15-deoxydelta12,14 prostaglandin J2 against the multiple organ failure caused by endotoxin. Crit Care Med 2004; 32:826-831
20. Abdelrahman M, Collin M, Thiemermann C: The peroxisome proliferator-activated receptor-gamma ligand 15-deoxyDelta12,14 prostaglandin J2 reduces the organ injury in hemorrhagic shock. Shock 2004; 22:555-561
21. Dugo L, Collin M, Cuzzocrea S, et al: 15d-prostaglandin J2 reduces multiple organ failure caused by wall-fragment of Gram-positive and Gram-negative bacteria. Eur J Pharmacol 2004; 498:295-301
22. Cuzzocrea S, Pisano B, Dugo L, et al: Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces the development of nonseptic shock induced by zymosan in mice. Crit Care Med 2004; 32:457-466
23. Liu D, Zeng BX, Zhang SH, et al: Rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, reduces acute lung injury in endotoxemic rats. Crit Care Med 2005; 33:2309-2316
24. Moller DE, Berger JP: Role of PPARs in the regulation of obesity-related insulin sensitivity and inflammation. Int J Obes Relat Metab Disord 2003; 27(Suppl 3):S17-S21
25. Pershadsingh HA: Peroxisome proliferator-activated receptor-gamma: Therapeutic target for diseases beyond diabetes: Quo vadis? Expert Opin Investig Drugs 2004; 13:215-228
26. Rosenzweig HL, Lessov NS, Henshall DC, et al: Endotoxin preconditioning prevents cellular inflammatory response during ischemic neuroprotection in mice. Stroke 2004; 35:2576-2581
27. Chatterjee PK, Zacharowski K, Cuzzocrea S, et al: Lipoteichoic acid from Staphylococcus aureus reduces renal ischemia/reperfusion injury. Kidney Int 2002; 62:1249-1263
28. Sivarajah A, McDonald MC, Thiemermann C: The cardioprotective effects of preconditioning with endotoxin, but not ischemia, are abolished by a peroxisome proliferator-activated receptor-gamma antagonist. J Pharmacol Exp Ther 2005; 313:896-901
29. Zacharowski K, Frank S, Otto M, et al: Lipoteichoic acid induces delayed protection in the rat heart: A comparison with endotoxin. Arterioscler Thromb Vasc Biol 2000; 20:1521-1528
30. Zacharowski K, Chatterjee PK, Thiemermann C: Delayed preconditioning induced by lipoteichoic acid from B. subtilis and S. aureus is not blocked by administration of 5-hydroxydecanoate. Shock 2002; 17:19-22
31. Fan H, Cook JA: Molecular mechanisms of endotoxin tolerance. J Endotoxin Res 2004; 10:71-84
32. Bauer P, Welbourne T, Shigematsu T, et al: Endothelial expression of selectins during endotoxin preconditioning. Am J Physiol Regul Integr Comp Physiol 2000; 279: R2015-R2021
33. Hiasa G, Hamada M, Ikeda S, et al: Ischemic preconditioning and lipopolysaccharide attenuate nuclear factor-kappaB activation and gene expression of inflammatory cytokines in the ischemia-reperfused rat heart. Jpn Circ J 2001; 65:984-990
34. Kota BP, Huang TH, Roufogalis BD: An overview on biological mechanisms of PPARs. Pharmacol Res 2005; 51:85-94
35. Von Knethen AA, Brune B: Delayed activation of PPARgamma by LPS and IFN-gamma attenuates the oxidative burst in macrophages. FASEB J 2001; 15:535-544
36. Leesnitzer LM, Parks DJ, Bledsoe RK, et al: Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. Biochemistry 2002; 41:6640-6650
37. Collin M, Abdelrahman M, Thiemermann C: Endogenous ligands of PPAR-gamma reduce the liver injury in haemorrhagic shock. Eur J Pharmacol 2004; 486:233-235
38. Thiemermann C, Ruetten H, Wu CC, et al: The multiple organ dysfunction syndrome caused by endotoxin in the rat: Attenuation of liver dysfunction by inhibitors of nitric oxide synthase. Br J Pharmacol 1995; 116:2845-2851
39. Lee G, Elwood F, McNally J, et al: T0070907, a selective ligand for peroxisome proliferator-activated receptor gamma, functions as an antagonist of biochemical and cellular activities. J Biol Chem 2002; 277:19649-19657
40. Collino M, Patel NS, Lawrence KM, et al: The selective PPARgamma antagonist GW9662 reverses the protection of LPS in a model of renal ischemia-reperfusion. Kidney Int 2005; 68:529-536
41. Baue AE: The multiple organ or system failure syndrome. In: Pathophysiology of Shock, Sepsis, and Organ Failure. Schlag G, Redl H (Eds). Berlin, Springer Verlag, 1993, pp 1004-1018
42. Hewett JA, Jean PA, Kunkel SL, et al: Relationship between tumor necrosis factor-alpha and neutrophils in endotoxin-induced liver injury. Am J Physiol 1993; 265:G1011-G1015
43. Ruetten H, Thiemermann C: Effects of tyrphostins and genistein on the circulatory failure and organ dysfunction caused by endotoxin in the rat: A possible role for protein tyrosine kinase. Br J Pharmacol 1997; 122:59-70
44. West MA, Heagy W: Endotoxin tolerance: A review. Crit Care Med 2002; 30:S64-S73
45. Brown JM, Grosso MA, Terada LS, et al: Endotoxin pretreatment increases endogenous myocardial catalase activity and decreases ischemia-reperfusion injury of isolated rat hearts. Proc Natl Acad Sci U S A 1989; 86:2516-2520
46. Ueda T, Toyoshima Y, Kushihashi T, et al: Effect of dimethyl sulfoxide pretreatment on activities of lipid peroxide formation, superoxide dismutase and glutathione peroxidase in the mouse liver after whole-body irradiation. J Toxicol Sci 1993; 18:239-244
47. Ashwood-Smith MJ: Radioprotective and cryoprotective properties of dimethyl sulfoxide in cellular systems. Ann N Y Acad Sci 1967; 141:45-62
48. Bishop-Bailey D: Peroxisome proliferator-activated receptors in the cardiovascular system. Br J Pharmacol 2000; 129:823-834
49. Abdelrahman M, Sivarajah A, Thiemermann C: Beneficial effects of PPAR-gamma ligands in ischemia-reperfusion injury, inflammation and shock. Cardiovasc Res 2005; 65:772-781
50. Bell-Parikh LC, Ide T, Lawson JA, et al: Biosynthesis of 15-deoxy-delta12,14-PGJ2 and the ligation of PPARgamma. J Clin Invest 2003; 112:945-955
51. Gilroy DW, Colville-Nash PR, Willis D, et al: Inducible cyclooxygenase may have anti-inflammatory properties. Nat Med 1999; 5:698-701
52. Leininger MT, Portocarrero CP, Houseknecht KL: Peroxisome proliferator-activated receptor gamma1 expression in porcine white blood cells: Dynamic regulation with acute endotoxemia. Biochem Biophys Res Commun 1999; 263:749-753
53. Takayama K, Yuhki K, Ono K, et al: Thromboxane A2 and prostaglandin F2alpha mediate inflammatory tachycardia. Nat Med 2005; 11:562-566
54. Schopfer FJ, Lin Y, Baker PR, et al: Nitrolinoleic acid: an endogenous peroxisome proliferator-activated receptor gamma ligand. Proc Natl Acad Sci U S A 2005; 102:2340-2345